drugset
drugset / Trial / NCT05897008

The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity

NCT05897008 ↗

Phase 1 Completed 114 enrolled Taizhou Mabtech Pharmaceutical Co.,Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

A phase 1, randomized, double-blind, parallel group, single-dose study to compare the pharmacokinetics, pharmacodynamics, safety and immunogenicity of two formulations of Omalizumab (CMAB007 and Xolair) in healthy subjects.

Timeline

Start
2022-02-07
Primary completion
2022-06-27
Completion
2022-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Omalizumab Monoclonal antibody 150 mg Subcutaneous

Indications

No indication recorded.